The world’s first self-powered DNA preservation pendant

Modern civilization lacks secure, sovereign infrastructure for personal biology and identity.

• When disaster strikes, medical and identity records vanish.
  
• Billions remain without reliable health data access or identity continuity.
  
• DNA is lost forever after death — with no legacy infrastructure to preserve it.
  
• Existing systems are fragmented, centralized, and fragile.

No unified system exists that can protect and preserve the essence of a person — across time, terrain, and even planetary boundaries.

-

The Solution:

AmberCore™ is the world’s first self-powered, biometric vault designed to survive disaster, preserve DNA, and signal location — all from a wearable pendant.

• Stores medical & DNA data in decentralized vaults
  
• Works offline via solar + kinetic energy
  
• Survives radiation, EMP, and planetary extremes
  
• Sends real-time SOS, health, and recovery signals
  
• Acts as a personal archive for biological and identity continuity
  

This is resilient biotech. Built to protect life — anywhere on Earth or beyond.

Ecosystem Modules:

• Biometric OS – Secure login, emergency diagnostics, and AI dispatch
  
• Rejuvenation Pods – DNA-personalized recovery tools
  
• OpenArchive Earth™ – Decentralized vaulting + identity re-verification
  
• Emergency Sync Protocol – Post-disaster recovery & biometric reactivation
  

One device. One vault. Infinite integrations. Caliteco is engineering a modular platform with compounding network effects.

Revenue Channels:

• Direct sales of hardware (60–80% margins)
  
• Recurring subscription vaulting & recovery services
  
• OEM integrations (military, aerospace, hospitals)
  
• Licensing to governments and institutional partners
  

35–50% of users expected to adopt subscriptions.
Multi-decade licensing potential with governments and medical systems.

-

ROI Table — Conservative vs. Optimistic Scenarios by 2030

Assumes $100M valuation cap at entry. Pro-rata ownership applied.

Figures based on cumulative net profit projections by 2030, using conservative (2.6M units) and optimistic (11.2M units) sales models.
Profit includes hardware, subscriptions, licensing, and infrastructure services.

These profit-share returns are only part of the upside — the same equity stake can multiply further in value during a full or partial exit.

-

Per-Share ROI — Current Round ($1.00/share)

At $1.00/share in the current round, early investors could see per-share values reach hundreds or even thousands by 2030, depending on full market activation and scaled deployment.

Projection reflects full cumulative return from all revenue streams through 2030, including vaulting, ARIN, OEM licensing, and high-margin hardware sales.

Based on 10M authorized shares, with 2.5M shares allocated in the current round at $1.00/share.

⚠️ Reality check: figures above are undiluted seed MOICs.
• If total shares outstanding rise to 18 M through future Series A–C rounds and ESOP, seed MOIC compresses to 38 × (conservative) – 185 × (optimistic).
• Equivalent pre-tax IRR: 55 % – 88 % over six years.

1. Hardware Sales

High-margin biometric devices in two trims:

Target markets: sovereign users, explorers, responders, families.
Projected blended hardware margin: 70 – 75 %.

2. Recurring Subscriptions

Encrypted DNA vaulting via OpenArchive.earth, ARIN emergency ID sync, sovereign recovery services, and institutional accounts.

• Projected adoption: 35 – 50 % of hardware users
  
• Average revenue per user (ARPU): $150 (consumer + pro mix)
  
• Service gross margin: ~ 75 %
  
• ARR potential by 2030:
  
• At 35 % adoption of 2.6 M units → ≈ $140 M+ ARR
  
• At 50 % adoption of 11.2 M units → ≈ $840 M+ ARR
  
• Contracts are multi-year, low-churn, and can secure decades of forward revenue in advance.
  

(Subscriptions boost recurring income and stabilize cash flow, reducing reliance on new hardware sales.)

3. Institutional Licensing

Strategic government & OEM contracts (military, aerospace, emergency ops) with multi-year revenue potential from B2G partnerships.

AmberCore™ blends high-margin hardware with recurring revenue and sovereign-scale licensing, creating a defensible, infrastructure-grade growth model.

• R&D Finalization – Hardware modules, encryption firmware, biometric sensors, and vault sync systems
  
• Tooling & Manufacturing – Swiss-grade components, custom titanium housing, energy cell supply chain, and OEM partner validation
  
• Node Infrastructure – Deployment of ARIN (AmberCore Rescue Intelligence Network) emergency relay grid and OpenArchive.earth sovereign backup vaults across priority geographies
  
• Regulatory Clearance – Compliance with biometric, DNA, medical device, and encryption standards across US, EU, and Swiss jurisdictions
  
• Strategic Partnerships & Outreach – Activation of early-stage channels with governments, aerospace, emergency response, and hospital networks
  

Execution is modular, fast-moving, and revenue-aligned — focused on go-to-market readiness and infrastructure scale.

• High-barrier market entry — sovereign, encrypted, off-grid network with AI-driven location and biometric relay.
  
• Recurring data subscription revenue from agencies, emergency services, and high-risk industries.
  
• Cross-sector adoption from maritime, aerospace, defense, and disaster relief organizations.
  

Investor Note: ARIN’s deployment phase is a scalable infrastructure build, not a one-off product launch. Early investment accelerates:

• Satellite and drone integration for low-orbit and terrain-challenged coverage.
  
• AI-driven data processing for real-time response.
  
• Strategic alignment with established space, defense, and health agencies.

• Redundant global nodes storing encrypted, serialized DNA & biometric data.
  
• Authentication through AmberCore™ — only the device owner’s biometric key can retrieve data.
  
• Reproduction on demand — identical replacements can be produced if the original is lost.
  

Investor Note: AmberCore™ Data Center transforms AmberCore™ pendant from a high-margin biotech device into a perpetual data infrastructure business, with:

• Long-term subscription revenue for secure vaulting.
  
• Government and institutional licensing for national-scale biometric continuity programs.
  
• Strategic positioning in the $21B+ DNA storage and preservation market.

Caliteco operates with surgical focus. Our manufacturing partners are secured, tooling is mapped, and lab infrastructure is scoped. We're not pitching hypotheticals — we're executing.

Milestones:

• Finalize manufacturing tooling
• Deploy Alpha + Beta hardware units (OEM + DTC)
• Launch DNA vaulting pipeline and biobank node infrastructure
• Deploy ARIN live rescue network integration and OpenArchive.earth secure vault infrastructure.
• Begin encrypted ecosystem sync across regions
• Regulatory alignment + early contracts activation

This isn’t a multiyear burn. It’s a 6-month sprint to product, platform, and return visibility.

Technical Risk

While core technologies are already functional, advanced module development (e.g. signal recovery, dry-state vaulting) requires rigorous validation and testing under extreme conditions.

Regulatory Complexity

DNA storage and biometric data transmission span overlapping jurisdictions. Regulatory frameworks are evolving and vary across countries. Caliteco is actively engaging with legal advisors in US, EU, and Swiss markets to ensure compliance.

Supply Chain Dependencies

AmberCore relies on precision components (e.g. titanium housing, custom energy cells). Geopolitical or logistical disruptions may affect manufacturing timelines. Dual-source strategies and on-continent fabrication partners are in progress.

Market Adoption Timing

While global trends favor sovereign health tools, mass market education and trust-building will be required. Caliteco’s phased rollout (explorers → medical → family markets) is designed to de-risk timing mismatches.

Strategic Execution

As a multi-disciplinary platform, success hinges on synchronized execution across engineering, manufacturing, legal, and distribution. The founding team and advisors bring over 30 years of international experience in high-complexity environments.

We believe these risks are not only manageable — but strategic — and have embedded resilience and redundancy into every layer of our architecture and operations.

Two Scenarios: Conservative vs. Optimistic by 2030:

Net profit combines hardware gross profit (Base $195/unit, Pro $735/unit, 70 / 30 mix) plus high-margin subscription (OpenArchive + ARIN) and institutional-licensing income, all of which scale with deployment.

Revenue drivers:

• Hardware sales (OEM ＋ DTC)
  
• Subscriptions (OpenArchive vaulting, ARIN rescue-grid, sovereign recovery)
  Projected adoption: 35 – 50 % of hardware users → $120 – $180 ARPU, ~75 % margin
  
• Institutional licensing (gov, health, defense sectors)
  

These channels blend high-margin upfront sales with decades-long recurring revenue.

• Hardware ＋ Services CAGR: 34 – 52 %
  
• Global TAM: $100 B+ across sovereign health, DNA tech, emergency response
  

Early execution and defensible positioning unlock a durable market edge. Subscription services alone are projected to add $110 M – $1 B ARR by 2030, stabilizing cash-flow and reducing reliance on new-device cycles.

Investor note: Under these growth scenarios, projected company valuations reach $5.7 B (conservative) to $26 – 28 B (optimistic) by 2030, supporting profit-share returns of 14 × – 97 × and equity multiples of 570 × – 3 800 ×, depending on adoption and market traction.

Investor Upside Example. At $1.00/share in the current round, projected per-share values by 2030 could reach:

Projection reflects full cumulative return from all revenue streams through 2030, including vaulting subscriptions, ARIN services, OEM licensing, and high-margin hardware sales.

Beyond profit-share, AmberCore™’s defensible IP and scalable infrastructure open the door to multiple high-value exit routes — each designed to maximize investor return.

Exit valuation = Net profit × 17× exit multiple.

• M&A by Biotech, HealthTech, or Defense Conglomerates
  DNA storage, biometric infrastructure, and emergency response are priority targets for enterprise acquisition.
• Acquisition by AI/Cloud Infrastructure Firms
  Companies like Palantir, Google Health, or AWS Health Data Services increasingly seek sovereign data primitives for identity + health.
• Private Equity Roll-Up in Sovereign Tech
  As demand grows for off-grid, durable identity and health stacks, sovereign tech is becoming a structured acquisition theme.
• IPO / Public Offering
  With cross-market utility (consumer, institutional, defense, and space), AmberCore is positioned to mature into a category-defining public offering.

-

Investor Multipliers:

• IP Leverage — Patents, protocols, and biometric data handling infrastructure are licensable across global jurisdictions.
  
• Recurring Revenue — DNA vaulting, biometric sync, and recovery protocols support predictable, high-margin recurring revenue.
  
• Mission-Critical Use Cases — From hospitals to orbital deployments, the defensibility and integration depth increase enterprise valuation multiples.

Bottom line:
This isn’t a consumer app exit. This is asymmetric upside through IP, infrastructure, and long-term utility — backed by a clear, acquirable stack.